Premium
Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity
Author(s) -
Han Ji H.,
Shin Hanho,
Rho Jun G.,
Kim JungEun,
Son Dong H.,
Yoon Juhwan,
Lee Yong J.,
Park JungHyuck,
Song Byung J.,
Choi ChangSik,
Yoon Seul G.,
Kim Il Y.,
Lee Eun K.,
Seong Je K.,
Kim Ki W.,
Kim Wook
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13350
Subject(s) - rimonabant , adipose tissue , inflammasome , inflammation , endocrinology , medicine , endocannabinoid system , white adipose tissue , proinflammatory cytokine , cannabinoid , insulin resistance , cannabinoid receptor , receptor , antagonist , diabetes mellitus
Aim To analyze the metabolic parameters and adipose tissue inflammation via NLRP3 inflammasome following chronic treatment of mouse models of obesity with AJ5018 as the peripherally restricted cannabinoid 1 receptor (CB1R) antagonist. Materials and methods The selectivity for CB1R over CB2R, brain/plasma concentration ratio, and centrally mediated neurobehavioural effects of AJ5018, were assessed. The long‐term effects of AJ5018 and rimonabant on the metabolic parameters and adipose tissue inflammation were analyzed in diet‐induced obese (DIO) mice and diabetic db/db mice. Results AJ5018 had a higher degree of selectivity for CB1R over CB2R and markedly reduced brain penetrance, as reflected by the lower brain/plasma concentration ratio and the attenuated centrally mediated neurobehavioural effects, compared with its brain‐penetrant parent compound rimonabant. In DIO and db/db mice, AJ5018 exhibited comparable effects to rimonabant in improving metabolic abnormalities and suppressing macrophage infiltration into white adipose tissue, activation of the NLRP3 inflammasome, and production of proinflammatory cytokines. Conclusions These results suggest that peripheral CB1R blockade improves obesity‐induced insulin resistance by suppressing adipose tissue inflammation via the NLRP3 inflammasome.